NFE2L2 and lung carcinoma: One study showed that the function of the NFE2L2 gene, which encodes NRF2, could be disrupted using CRISPR/Cas9 technology, which leads to increased sensitivity of lung cancer cells to cisplatin, vinorelbine, and carboplatin [134].